# **OPTIMA HEALTH PLAN**

# PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If the information provided is not complete, correct, or legible, the authorization process may be delayed.

# **Please Note: Infertility Treatment is a Group-Specific Benefit**

#### **Drug Requested:** (select from below):

□ <b>Novarel</b> <sup>®</sup> (chorionic gonadotropin)	□ <b>Ovidrel</b> <sup>®</sup> (choriogonadotropin alfa)
□ <b>Pregnyl</b> <sup>®</sup> (chorionic gonadotropin)	chorionic gonadotropin

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Form/Strength:

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

# For 2 Month Approval for Prepubertal Cryptorchidism:

- □ Patient is between 4-9 years of age; AND
- □ Patient has a diagnosis of prepubertal cryptorchidism **NOT** due to anatomical obstruction

# Medication being provided by Specialty Pharmacy - PropriumRx

# Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required. \*\* Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\* \*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\*

Member Name:	
Member Optima #:	
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
* Annroyad by Pharmany and Thoranautics Committ	

Approved by Pharmacy and Therapeutics Committee: 4/19/2018 REVISED/UPDATED: 6/17/2018; Reformatted 1/8/2020; 11/1/2021;